Phase 1 Trial of Intratumoral Administration of NIS-Expressing Strain of Measles Virus in Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor
Technical Report,15 Sep 2017,14 Sep 2018
Mayo Clinic Rochester United States
Pagination or Media Count:
Study approved by Mayo IRB on April 18, 2016, and by USAMRMCORPHRPO on May 6, 2016. All study staff completed IRB training. Dose volume charts have been developed to facilitate pharmacy orders. Study opened for enrollment on May 17, 2016. Study coordinators identified and assigned to the study by Mayo Clinic Cancer Center. Three patients have been enrolled in the study. They completed treatment per protocol and continue the follow up. None of the treated patients experienced side effects. With the first 3 patients we have completed the first dose level. One patient has been currently on study after receiving second dose level. So far out of 4 treated patients one died to cancer progression. Others are undergoing follow up. An additional patient is under evaluation for eligibility at this time.
- Medicine and Medical Research